GALAFOLD caps 123 mg 14 pce

7680661080011 CH-66108 A16AX14 07.99.0.

Reimbursement limitations:

GALAFOLD3

Le traitement nécessite l’accord sur la prise en charge des frais par l’assureur-maladie après consultation …

GALAFOLD caps 123 mg 14 pce
GALAFOLD caps 123 mg 14 pce
GALAFOLD caps 123 mg 14 pce
1 / 3
google

Details

Product number
6610801
CPT
-
Packaging group
14
Unit
Kapsel(n)
Composition
migalastatum 123 mg ut migalastati hydrochloridum, amylum pregelificatum, magnesii stearas, Kapselhülle: gelatina, E 171, E 132, Drucktinte: lacca, E 172 (nigrum), kalii hydroxidum, excipiens pro capsula.

Articles (1)

Galafold 123 mg, Kapseln
Kapseln
14
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
11/06/2025
Patient information leaflet
Français
11/06/2025
Patient information leaflet
Italien
11/06/2025
Professional SmPC
Allemand
11/06/2025
Professional SmPC
Français
11/06/2025
Professional SmPC
Italien
11/06/2025

Detailed composition

Substance Quantity Type Category
(N/A)
123.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FNIDK
(N/A)
- Substance FIMDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 18431.65
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/03/2017

Authorization holder

Amicus Therapeutics Switzerland GmbH

8008 Zürich

Authorization information

Swissmedic authorization number
66108
Drug name
Galafold, Kapseln
Galenic form
KAHA
ATC Code
A16AX14
Authorization status
Z
Dispensation category
B
First authorization
28/10/2016
Authorization expiration date
31/12/9999
IT number
07.99.0.
Domain
Human medicine
Field of application
Morbus Fabry

Packaging details

Description (FR)
GALAFOLD caps 123 mg 14 pce
Description (DE)
GALAFOLD Kaps 123 mg 14 Stk
Market launch
28/10/2016
Narcotic (BTM)
No